Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) reported second quarter 2021 revenue of €204.0 million, a 26% increase year-on-year, with gross margins rising to 31.2%. Net profit was €34.5 million, equating to €0.14 diluted EPS, including a €4.4 million one-time benefit. Adjusted diluted EPS was €0.12. The company forecasts 2021 revenue between €820 million and €830 million, with adjusted EPS expected to be between €0.43 and €0.47. Strong demand in its biopharmaceutical segment, driven by high-value solutions, contributed to growth. The company raised approximately $453.5 million in its IPO.
Summary not available.
Stevanato Group has priced its initial public offering of 32 million ordinary shares at $21 each, set to trade on the NYSE under the ticker symbol STVN starting July 16, 2021. The offering is anticipated to close on July 20, 2021, subject to standard conditions. Additionally, underwriters have a 30-day option to purchase 4.8 million more shares. The company has also entered into hedging agreements for $420 million and $180 million with Morgan Stanley to address currency exposure from the proceeds.